FibroGen (FGEN) Appoints Michael Kauffman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
June 9, 2025 4:02 PM EDTSAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board, said James Schoeneck, chairman of the board of directors of FibroGen. His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michaels deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers.
FibroGen has differentiated potential... More



